Celgene price target lowered to $76 from $102 at Rodman & Renshaw Rodman & Renshaw lowered Celgene citing the withdrawal of Revlimid's new indication submission to the CHMP. Shares are Outperform.
News For CELG From The Last 14 Days
Check below for free stories on CELG the last two weeks.